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Objective: Isolated lung perfusion allows the delivery of high-dose chemo- 
therapy to the perfused lung and is an efficacious modality in the treatment 
of pulmonary metastases in the rat. Melphalan activity in this model was 
investigated. Methods: Tox~crrv STUDY: Maximum tolerated ose of melpha- 
lan delivered by means of isolated lung perfusion was determined by 
survival after contralateral pneumonectomy. PHARMACOKINETICS STUDY: 
Nineteen rats were treated with me|phalan administered either by isolated 
lung perfusion (2 mg) or intravenously (2 mg or 1 mg). Lung, pulmonary 
effluent, and serum melphalan were analyzed by high-pressure liquid 
chromatography. EFFICACY STUDY: On day 0, 41 rats received an intravenous 
injection of 5 x 106 methylcholanthrene i duced sarcoma cells. On day 7, 
rats either received intravenous melphalan (2 mg [n = 10]; 1 mg [n = 8]) 
or underwent left isolated lung perfusion with 2 mg of melphalan (n = 12). 
Isolated lung perfusion with buffered hetastarch in sodium chloride 
(Hespan, n = 11) was used as control. On day 14, pulmonary nodules were 
counted. Results: TOXICITY: Maximum tolerated ose of melphalan delivered 
buy means of isolated lung perfusion was 2 mg. PHARMACOKINETICS: Left 
lung melphalan level was significantly higher in the isolated lung perfusion 
group (62.2 - 34.3/~g/gm lung) than in the intravenous treatment groups 
(6.9 -+ 1.9/~g/gm lung and 3.3 - 0.9/~g/gm lung, respectively) (p = 0.0002). 
EFFICACY: Significantly fewer left lung nodules were found in animals 
receiving melphalan by means of isolated lung perfusion (7 - 10) than in 
the groups receiving intravenous melphalan (60 -+ 21) or buffered 
hetastarch by isolated lung perfusion (84 - 52) (p = 0.01 and p = 0.0001, 
respectively). Conclusion: Isolated lung perfusion with melphalan is safe 
and effective in the treatment of pulmonary sarcoma metastases in the rat. 
(J Thorac Cardiovasc Surg 1996;112:1542-8) 
T he treatment of metastatic pulmonary sarcoma poses a significant clinical problem. Isolated pul- 
monary metastases will develop in approximately 
20% of patients with soft tissue sarcoma of the 
extremities. Systemic chemotherapy holds little 
From the Thoracic Oncology Laboratory/Department of Surg ry, 
Memorial Sloan-Kettering Cancer Center, New York, N.Y. 
Read at the Seventy-sixth Annual Meeting of The American 
Association for Thoracic Surgery, San Diego, Calif., April 
28-May 1, 1996. 
Received for publication May6, 1996; revisions requested June 
24, 1996; revisions received August 9, 1996; accepted for 
publication August 13, 1996. 
Address for reprints: Michael Burt, MD, PhD, Memorial Sloan- 
Kettering Cancer Center, Department of Surgery, 1275 York 
Ave., New York, NY 10021. 
Copyright © 1996 by Mosby-Year Book, Inc. 
0022-5223/96 $5.00 + 0 12/6/77326 
1542 
promise for long-term survival. Although surgical 
resection remains the mainstay of treatment, 5-year 
survival approaches only 25%. 2.2 Medical treatment 
failures are related to a high degree of sarcoma 
chemoresistance and the toxicity of therapy. Surgi- 
cal treatment failures appear to be related to micro- 
metastatic disease present at the time of surgical 
resection. 5 
We have developed a rodent model of isolated 
lung perfusion (ILP) to test a novel treatment 
strategy for pulmonary metastases. 6 ILP allows the 
delivery of high-dose chemotherapy to the perfused 
lung while preventing systemic toxicity. 7 Our labo- 
ratory has shown that metastatic sarcoma nodules 
can be eradicated with doxorubicin given by means 
of ILP?  Doxorubicin is widely considered an effec- 
tive agent against metastatic sarcoma. Many pa- 
tients eligible to enter the ongoing phase I human 
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ILP trial at the Memorial Sloan-Kettering Cancer 
Center have previously received the maximum tol- 
erated systemic doses of doxorubicin. The availabil- 
ity of alternate agents for perfusion is, therefore, 
important, because emergence of chemoresistance 
to doxorubicin is a potential concern. Melphalan 
(L-PAM) has been shown to be an effective agent 
against soft tissue sarcoma when delivered via iso- 
lated limb perfusion. 9-13 Evaluations of toxicity and 
efficacy of melphalan in an ILP model are of clinical 
interest in formulation of future treatment strategies 
against metastatic pulmonary sarcoma. 
Material and methods 
Animal care. Male Fischer F344 rats (Charles River 
Laboratories, Kingston, N.Y.) were used in all experi- 
ments. Animals were treated in accordance with the 
Animal Welfare Act and the "Guide for the Care and Use 
of Laboratory Animals" (NIH Publication No. 86-23, 
revised 1985). All experiments were approved by the 
Institutional Animal Care and Use Committee of Memo- 
rial Sloan-Kettering Cancer Center. Animals were al- 
lowed access to standard laboratory rat chow (Purina Rat 
Chow; Ralston Purina, St. Louis, Mo.) and water ad 
libitum. Housing was temperature controlled and pro- 
vided a 12-hour light/dark cycle. 
Preparation of tumor. The tumor used in efficacy ex- 
periments was a methylcholanthrene-induced sarcoma. 
This sarcoma has been serially passed subcutaneously in 
our laboratory and has been well characterized. 14'15 Tu- 
mor was harvested fresh from a tumor-bearing animal, 
and a single cell suspension was prepared. The suspension 
was created by mincing tumor into 1 mm 3 chunks, then 
digesting the chunks in 0.8% Collagenase D solution 
(Boehringer Mannheim GmbH, Mannheim, Germany) 
for 45 minutes at 37 ° C. The suspension was washed twice 
in phosphate-buffered saline solution. Bilateral pulmo- 
nary metastases can be reproducibly established by injec- 
tion of this cell suspension i to an external jugular vein at 
a concentration of 5 × 10 6 cells/ml. 
ILP. ILP via the left lung was performed by the method 
previously established in this laboratory. 6 Animals were 
anesthetized with pentobarbital sodium (50 mg/kg) intra- 
peritoneally and intubated endotracheally with a 16-gauge 
intravenous catheter under direct visualization through an 
otoscope, t6A Harvard Apparatus rodent volume ventila- 
tor (model 683, Harvard Apparatus Co., Inc., South 
Natick, Mass.) was used to ventilate the animals' lungs 
with room air at a tidal volume of 10 ml/kg and at a 
respiratory rate of 80 strokes/min. Halothane was used to 
supplement anesthesia. The left side of the chest was 
shaved and prepared with a povidone-iodine 10% solu- 
tion, and a left thoracotomy through the fourth intercostal 
space was performed. The left pulmonary artery and vein 
were visualized under an operating microscope (OpMi-1, 
16 ×; Carl Zeiss, Wotan, Germany). Microvascular clamps 
were placed proximally on the pulmonary artery and vein. 
An arteriotomy was performed and the artery was cannu- 
lated with a PE-10 catheter (Becton Dickinson & Co., 
Parsippany, N.J.). Perfusate was delivered through this 
catheter. A pulmonary venotomy was created and effluent 
was collected by a suction catheter placed near the 
venotomy. At the completion of the perfusion, the arteri- 
otomy was repaired with a single simple suture (9-0 
Ethilon, Ethicon, Inc., Somerville, N.J.). The microvascu- 
lar clamps were removed and the left lung was returned to 
its anatomic position. Pressure was applied with gauze 
placed over the lung to control the bleeding from the 
venotomy. Through a separate puncture wound, a 16- 
gauge catheter connected to a 5 ml syringe was introduced 
into the left side of the chest cavity to facilitate lung 
reexpansion. The thoracotomy incision was closed in three 
layers with 4-0 silk. When the animals were alert and 
breathing spontaneously, the chest and endotracheal 
tubes were removed. 
In all experiments, animals were perfused for 20 min- 
utes with melphalan (Alkeran, Burroughs Wellcome Co., 
Research Triangle Park, N.C.) or buffered 6% hetastarch 
in 0.9% sodium chloride solution (BHE) (Hespan, Du 
Pont Pharmaceuticals, Wilmington, Del.) at a rate of 0.5 
ml/min. In the toxicity and efficacy studies, rats underwent 
5-minute washout with BHE at 0.5 ml/min. In the phar- 
macokinetics tudy, rats underwent 10-minute washout 
with BHE. All doses of melphalan represent total doses 
administered to each animal. Melphalan perfusate solu- 
tions were prepared by reconstituting lyophilized powder 
in the supplied diluent and performing appropriate dilu- 
tions with BHE. 
Experiment 1: Toxicity study. On day 0, 29 male F344 
rats (235 to 275 gin) were randomized into six groups. 
Group I (n = 2) had ILP with 20 mg of melphalan, group 
II (n = 6) had ILP with 5 mg of melphalan, group III (n = 
6) had ILP with 2 mg of melphalan, and group IV (n = 5) 
had ILP with BHE. Groups V (n = 5) and VI (n = 5) 
received 2 mg or 1 mg of melphalan via the external 
jugular vein. All animals underwent right (contralateral) 
pneumonectomy on day 21 to assess left lung function. On 
day 38, arterial blood gases were measured in animals that 
survived contralateral pneumonectomy. Arterial blood 
samples were collected from the abdominal aorta of the 
anesthetized animals. Animals were subsequently put to 
death, and the lungs were retrieved and stained with 
hematoxylin and eosin for histologic examination. Daily 
weight was recorded after ILP or intravenous treatments. 
Experiment 2: Pharmacokinetics. Nineteen male F344 
rats (250 to 300 gin) were randomized into three groups. 
Group I (n = 8) had ILP with 2 mg of melphalan. Group 
II (n = 5) and group III (n = 6) received 1mg or 2 mg of 
melphalan via external jugular venous injection. The ILP 
group had a PE-90 (Becton Dickinson) catheter inserted 
into the pulmonary vein for collection of pulmonary 
effluent samples. The pulmonary effluent samples were 
collected at 2-minute intervals throughout the perfusion. 
At the completion of a 20-minute melphalan perfusion 
and 5-minute BHE washout, blood samples were collected 
by cardiac puncture and both lungs were removed and 
frozen at -70°C  for later melphalan analysis. Animals 
receiving intravenous melphalan underwent laparotomies 
20 minutes after injection, and blood samples were drawn 
from the abdominal aorta. Subsequently, the animals were 
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Table I. Perioperative survivals 
Perioperative survival (%) 
ILP Pneumonectorny 
Melphalan 20 mg (n = 2) 0 - -  
Melphalan 5 mg (n = 6) 100 0 
Melphalan 2 mg (n = 6) 100 67 
BHE (n = 5) 100 80 
Pneumonectomy indicates contralateral (right) pneumonectomy. 
put to death and both lungs were removed for measure- 
ment of melphalan tissue levels. 
Melphalan processing and measurement. High-pres- 
sure liquid chromatography (HPLC), based on the 
method escribed by Chang, 17 Scott, TM and their associ- 
ates, was used to measure melphalan concentration. Pul- 
monary effluent samples were centrifuged and superna- 
tants were frozen at -70°C for later processing. Tissue 
was homogenized in a siliconized glass homogenizer in
acidic buffer (water and methanol [1:1] with 1% acetic 
acid) in a 1:4 proportion and then centrifuged. Dansyl- 
proline (Sigma Chemical Company, St. Louis, Mo.) was 
used as an internal standard and was dissolved in metha- 
nol (0.25 txg/ml). Then 2 ml or 200 txl of internal standard 
solution was added to 1 ml of effluent supernatant or 100 
/xl of tissue homogenate supernatant. Samples were mixed 
vigorously on a vortex mixer, cooled at -60 ° C (acetone 
and Dry Ice) for 3 minutes, and centrifuged. The super- 
natant was analyzed by HPLC. The HPLC system con- 
sisted of a Perkin-Elmer pump series 410 LCI, Autosam- 
pler ISS 200, and integrator LCI 100 (Perkin-Elmer Corp., 
Plainview, N.J.). Melphalan was detected at 254 nm 
wavelength on spectrophotometric detector (model LC 
75, Perkin-Elmer Corp., Norwalk, Conn.). A 50 ~1 sample 
was injected into a Symmetry CTM reversed-phase 3.9 × 
150 mm HPLC column (Waters Corp., Milford, Mass.). 
The mobile phase was composed of water and methanol 
(1:1) with 1% acetic acid, at a flow rate of 1.5 ml/min. All 
chemicals were high purity (HPLC grade). 
Experiment 3: Efficacy study. Forty-one male F344 rats 
(225 to 275 gm) were randomized into four groups. On 
day 0, all groups underwent an intravenous injection of 
5 X 10 6 methylcholanthrene-induced sarcoma cells via the 
right external jugular vein. On day 7, group I (n = 10) 
received 2 mg of melphalan i travenously; group II (n = 
8) received 1 nag of melphalan intravenously; group III 
(n = 12) underwent ILP with 2 mg of melphalan; group 
IV (n = 11) underwent ILP with BHE. On day 14, rats 
were sacrificed and their lungs were stained with India ink 
for identification of pulmonary sarcoma nodules. 19 
Statistical analysis. All data are presented as mean + 
standard eviation. Pharmacokinetic data were analyzed 
by analysis of variance (ANOVA) test. Paired compari- 
sons of the efficacy data between the melphalan ILP and 
the intravenous or BHE treatment groups were per- 
formed by means of the independent Student's t test. 
Significance was defined as p < 0.05. 
Results 
Toxicity study. Rats undergoing isolated lung 
perfusion with 20 mg of melphalan died immedi- 
ately after perfusion. Animals perfused with 5 mg of 
melphalan survived ILP but died within a few hours 
after contralateral pneumonectomy. All animals 
perfused with 2 mg of melphalan or BHE survived 
ILP. Rats perfused with 2 mg of melphalan or BHE 
lost weight after ILP for 3 to 4 days and then 
recovered. Rats perfused with 2 mg of melphalan or 
BHE survived contralateral pneumonectomy at 
rates of 67% and 80%, respectively (Table I). Rats 
that received 2 mg of melphalan intravenously died 
within 5 days of injection. All rats receiving 1 mg of 
rnelphalan intravenously survived. 
The histologic examination of the perfused lungs 
in groups II through IV showed evidence of alveolar 
cell hyperplasia. The lungs harvested from animals 
in group I showed severe congestion and mild-to- 
moderate hemorrhage. Mild-to-moderate conges- 
tion and hemorrhage were seen in group II. Varying 
degrees of pleural fibrosis and pleuritis were found 
in all groups except group I (Fig. 1). Arterial blood 
gas analysis on day 38 revealed a significant differ- 
ence in oxygen tension, carbon dioxide tension, and 
pH between the melphalan ILP group and BHE ILP 
group (Table II). 
Pharmacokinetics tudy. Lung melphalan levels 
were measured for all groups. Left lung melphalan 
levels were significantly higher in the melphalan ILP 
group (62.2 + 34.3/xg/gm lung) than in the intrave- 
nous treatment groups (6.9 _+ 1.9 /xg/gm lung in 2 
rag, given intravenously, 3.3 _+ 0.9/xg/g lung in 1 rag, 
given intravenously) (Table III). Melphalan levels in 
the pulmonary venous effluent in the ILP group 
became elevated after 2 minutes and were almost 
constant throughout the 20 minutes of perfusion. At 
the end of the washout, melphalan levels of the 
venous effluents approached zero (Fig. 2). Serum 
melphalan levels in all groups were analyzed. No 
melphalan was detected in the serum of animals that 
received melphalan ILP. Serum melphalan levels in 
the groups receiving 1 mg and 2 mg intravenously 
were 1.5 + 0.5/xg/ml and 2.5 _+ 0.7/xg/ml, respec- 
tively (see Table III). 
Efficacy study. The number of left lung lesions 
was significantly less in animals receiving melphalan 
via ILP as compared with those receiving 1 mg of 
melphalan intravenously or BHE ILP (7 _+ 10 vs 
60 _+ 21 and 84 _+ 52) (Table IV). Melphalan ILP 
resulted in a significant reduction of tumor nodules 
in the treated left lung as compared with the right 
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Fig. 1. Histologic findings of the perfused lungs. A, Group I: ILP with 20 mg of melphalan. B, Group II: 
ILP with 5 mg of melphalan. C, Group III: ILP with 2 mg of melphalan. D, Group IV: ILP with BHE. 
(Original magnifications xl00.) 
Table II. Arterial blood gas analysis on day 38 
PO2 (mm Hg)* Pco2 (mm Hg)? pile 
Melphalan 2 mg ILP 61.5 ± 11.0 52.5 ± 7.3 7.39 _+ 0.05 
(n - 4) 
BHE ILP 90.5 +- 16.1 35.5 -+ 9.5 7.49 _+ 0.06 
(n = 4) 
*p = 0.02 
tp = 0.03 
'vp - 0.04 
Table III. Lung and serum melphalan levels 
Left lung Right lung Serum 
(tzg/g) (Ixg/g) (t-N/ml) 
Melphalan 2 mg ILP 62.2 _+ 34.3 0 0 
(n - 8) 
Melphalan 1 mg i.v. 3.3 + 0.9 2.4 _+ 1.4 1.5 + 0.5 
(n - 5) 
Melphalan 2 mg i.v. 6.9 ± 1.9 7.8 ± 5.3 2.5 _+ 0.7 
(n = 6) 
iv., Intravenous. 
lung (7 _+ 10 vs 185 _+ 70) (p = 0.000001). All rats 
that received melphalan 2 mg intravenously died 
within 5 days of injection. 
Discussion 
Isolated pulmonary metastases will develop in 
approximately 20% of patients with soft issue sar- 
coma of the extremities. 1 Surgical resection of pup 
monary metastases from soft tissue sarcoma is a 
widely accepted form of potentially curative therapy. 
However, the majority of these patients eventually 
die as a result of recurrence within the lung. 1 Failure 
of surgical treatment appears to be related to mi- 
crometastatic disease present at the time of surgical 
resection. 15 
In an attempt o address the clinical problem of 
micrometastatic pulmonary sarcoma, our laboratory 
developed a model of ILP in the rat. 6 ILP with 
doxorubicin was shown to be effective in eradicating 
metastatic sarcoma in the rats, and a phase I trial of 
doxorubicin ILP in man is underway. 
The present study evaluated melphalan as an 
antisarcoma agent delivered via ILP. Clinical studies 
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Fig. 2. Melphalan (L-PAM) levels of venous effluent after ILP with 2 mg of melphalan for 20 minutes and 
washout with BHE for 10 minutes. 
Table IV. The number of lung sarcoma nodules 
Left lung Right lung 
Melphalan 1 mg i.v. 60 _+ 21 66 -+ 23 
(~ = 8) 
Melphalan 2 mg ILP 7 _+ 10*T 185 _+ 70 
(n = 12) 
BHE ILP 84 -+ 52 201 -+ 51 
(~ = 11) 
i.v., Intravenous. 
*p = 0.01 vs. melphalan 1 mg i.v.; p = 0.0001 vs. BHE ILP. 
?p = 0.000001 vs. right lung. 
have revealed an antitumor esponse against soft 
tissue sarcoma of the extremities with isolated limb 
perfusion with melphalan alone and more recently 
with tumor necrosis factor and melphalan. 9-13' 20-22 
The effectiveness of melphalan against soft tissue 
sarcoma via ILP encouraged us to explore melpha- 
lan ILP for the treatment of pulmonary sarcoma 
"metastases." 
Toxicity studies determined the maximum toler- 
ated dose of melphalan i  our rat ILP model to be 
2 mg per rat, with 67% of the animals surviving 
subsequent contralateral pneumonectomy. All rats 
that received 2 mg of melphalan i travenously died 
within 5 days of injection. The 2 mg dose is equiv- 
alent to 8 mg/kg for a 250 gm rat. The previously 
reported 10% lethal dose for rats after intravenous 
injection of melphalan is 7 mg/kg, z3 
Lung levels of melphalan in the melphalan ILP 
group were 20 times as high as in the intravenous 
group. The elevated concentration f lung melphalan 
in the perfused left lung as compared with the right 
lung is consistent with results een in our doxorubicin 
study 7and confirms the ability to deliver higher levels 
of chemotherapeutic agents to the perfused, tumor- 
bearing organ than does intravenous administration. 
In the present study, pulmonary venous effluent levels 
of melphalan approached zero after 2 minutes of BHE 
washout. Therefore, asignificant systemic leak after a 
5-minute washout is not possible. 
An antitumor effect was evident in the left lungs 
of animals treated with melphalan ILP. Two rats 
showed a complete response. Combined synergistic 
modalities may enhance the tumoricidal effect of 
melphalan. Some investigators have used hyperther- 
mic isolated limb perfusion with melphalan against 
soft tissue sarcoma s a preoperative adjunct or as 
palliative therapy for unresectable tumor and report 
a local recurrence rate of 11% to 33% and a 5-year 
survival of 65% to 80%. 9-12 Hill and associates 22 
showed a 100% complete response rate in patient 
with soft tissue sarcomas of extremities by isolated 
limb perfusion with tumor necrosis factor and mel- 
phalan. 22 Rickaby, 24 Cowen, a5 and their colleagues 
have shown that hyperthermic lung perfusion is well 
tolerated by normal ung. Our laboratory has previ- 
ously revealed that isolated lung perfusion with 
tumor necrosis factor can be done safely in the rat 
and is effective in decreasing the growth of sarco- 
matous lung metastases. 26 
In conclusion, ILP with melphalan is safe and 
effective in the treatment ofsarcomatous pulmonary 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 112, Number 6 
Nawata et aL 1547 
metastases in the rat. Trials evaluating melphalan 
ILP in patients with isolated pulmonary metastases 
are warranted. 
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Discussion 
Dr. Frank Baciewicz (Detroit, Mich.). We have treated 
patients clinically with doxorubicin and have not been 
impressed with the results. In your study I noticed that a 
number of animals receiving BHE died just before con- 
tralateral pneumonectomy. The first question isthis: What 
does BHE do to the lung? Also, in your efficacy study it 
appeared that BHE caused a significant decrease in the 
number of nodules in the treated lung. It seemed that 
there was a good effect with just BHE. What effect does 
BHE have on the number of nodules in this model? 
Dr. Nawata. In our first experiment, all rats perfused 
with 20 mg of melphalan died immediately after perfu- 
sion, but rats perfused with BHE all survived perfusion, 
and 20% of these rats died after contralateral pneumo- 
nectomy. I think this mortality is not from a toxicity of 
BHE, but from a technical error. In our efficacy study, rats 
uriderwent 20-minute anoxic perfusion. I think this is why 
the BHE group demonstrated a reduction in the number 
of tumor nodules. 
Dr. Joe B. Putnam, Jr. (Houston, Tex.). Dr. Nawata, I
applaud the efforts that have gone into this work and, as 
well, the contributions that you and the surgeons at 
Memorial have made toward the treatment of pulmonary 
metastasis. The information you presented indicates value 
in isolated pulmonary perfusion for the treatment of 
pulmonary metastases in your animal model. However, 
the translation of this work from the animal model to the 
human being still is undergoing effort and revision. 
In your rat model the sarcoma cell line is homogeneous, 
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whereas in the human model sarcomas are heteroge- 
neous. Have you evaluated this drug in the treatment of 
other rat sarcoma cell lines? Second, how did the dose 
selected in your rat model compare with the dose that has 
been previously used in human beings for the isolated 
limb perfusion? 
Dr. Nawata. To answer the first question, we have not 
evaluated another sarcoma cell line in the rat. To answer 
the second question, in human isolated limb perfusion, 
previous reports howed that the melphalan concentration 
of tissue or tumor was dependent on melphalan concen- 
tration of perfusate. They used 60 to 80 mg of melphalan 
(0.6 to 1.0 mg/kg in the upper limb, 0.8 to 1.2 mg/kg in the 
lower limb). In our efficacy study, we used 2 mg of 
melphalan per rat (8 mg/kg). 
Dr. Keith S. Naunheim (St. Louis, Mo.). Dr. Nawata, 
can you tell us a little bit about the histology of the lung 
away from the sarcoma, what sort of inflammatory and 
damaging effects there are histologically from the melpha- 
lan? 
Dr. Nawata. Rats perfused with 20 mg of melphalan 
died immediately after ILP. Rats perfused with 5 mg of 
melphalan tolerated ILP but died after contralateral 
pneumonectomy. The lungs of those rats that were per- 
fused with 20 mg or 5 mg of melphalan showed severe 
hemorrhage and congestion. The lungs of the rats per- 
fused with 2 mg of melphalan had alveolar cell hyperplasia 
and pneumonitis characterized by mild-to-moderate in-
flammatory cell infiltration consisting primarily of mono- 
nuclear cells with occasional neutrophils that was similar 
to findings in the control group. 
Dr. Larry R. Kaiser (Philadelphia, Pa.). You inject the 
MCA sarcoma on day 0, and you wait until day 7 before 
you do your perfusion. Are there visible nodules at that 
time or are there just microscopic nodules? Have you 
looked at them at day 7? Also, have you looked at the 
immune component? That is, after treating these tumor- 
bearing animals, have you looked at the inflammatory 
cells that may be collecting in the lung as well? As was 
pointed out by, one of the discussants, even in your 
control group you had a reduction in the number of 
nodules. 
Dr. Nawata. We have not evaluated the role of the 
immune system in our model. 
Dr. Kaiser. Do you have visible nodules on day 7 in your 
model? 
Dr. Nawata. By day 7 we have microscopic disease. We 
can see macroscopic nodules by day 10 to 12. 
